Drug intelligence / Profile preview

APL-2006

Development stage: Discontinued
Lead developer: Apellis Pharmaceuticals
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Oral, Intravenous

Overview

APL-2006 was a preclinical bispecific inhibitor developed by Apellis Pharmaceuticals in collaboration with Affilogic. It targeted both complement C3 and vascular endothelial growth factor (VEGF) for the treatment of wet age-related macular degeneration (AMD) and geographic atrophy. The drug leveraged Affilogic's Nanofitin® technology. Apellis discontinued the development of APL-2006 in August 2023 to focus on commercializing other assets.

Targets

C3VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on APL-2006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APL-2006.

Explore the full profile